Stéphane Bancel, Moderna CEO (Lenin Nolly/NurPhoto via AP Images)
September 12, 2024 06:00 AM EDTUpdated 09:33 AM
R&D

Mod­er­na plans $1.1B in R&D and pro­gram cuts, de­lays break-even point to 2028

Andrew Dunn

Senior Biopharma Correspondent

Stéphane Ban­cel has re­lent­ed to Wall Street’s de­sire for cost-cut­ting and rein­ing in Mod­er­na’s pipeline.

To kick off its an­nu­al R&D day in New York …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Af­ter land­ing a key win in a com­mon can­cer con­di­tion, Pfiz­er faces a big test in Phase 3

23andMe heads to ES­MO to tout its two clin­i­cal-stage drugs af­ter scrap­ping dis­cov­ery team

Cigna sues FTC, call­ing for with­draw­al of 'bi­ased, er­ro­neous' PBM re­port

Mer­ck and Dai­ichi’s re­ject­ed HER3 ADC clears a Phase 3 in cer­tain lung can­cers

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times